Quantcast

Latest Phosphoinositide 3-kinase Stories

2014-09-03 08:32:32

- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer....

2014-05-08 23:06:59

According to a new report from BCC Research, the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%. (PRWEB) May 08, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, JAK AND PI3K SIGNALING PATHWAY MARKETS ,the global market for signal...

2014-04-09 08:28:30

QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T....

2014-04-01 08:28:18

QUÉBEC CITY, April 1, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California. Abstract#3711: "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and...

2014-01-07 14:18:21

Why inhibition of both pathways is important In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2. This reactivation of Akt limits quite efficiently the response of the tested tumor cell lines presenting constitutively active K-Ras activity (both through K-RAS mutation or...

Study Finds Drug-Resistant Melanoma Treatments May Be Enhanced
2013-11-22 09:27:11

April Flowers for redOrbit.com - Your Universe Online More than 8,000 Americans are killed each year by melanoma -- the deadliest form of skin cancer. The presence of mutations in a gene known as the BRAF gene drives approximately 40 percent of advanced melanoma tumors. New medications, called BRAF inhibitors, have shown an ability to rapidly shrink melanoma tumors, however BRAF-mutated tumors often resist early treatment and only partially respond to BRAF inhibitors, which leaves...

2013-11-05 10:35:52

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients. "It is still too premature to estimate when a clinical...

2013-10-05 23:02:44

Drivers of M&A in 2013-2016: Phosphoinositide 3-Kinases (PI3Ks) and Bruton’s Tyrosin Kinase (BTK) Inhibitors is the market research report available at ReportsnReports.com store. Dallas, Texas (PRWEB) October 05, 2013 Targeting kinases have been on the agenda of most drug developers/researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced...

Mutation Increases Melanoma Risk In Redheads
2013-08-23 04:22:04

April Flowers for redOrbit.com - Your Universe Online A person’s hair color and skin tone is determined by their skin pigment. This pigment is influenced by the melanocortin-1 (MC1R) gene receptor. For the world’s redheads – one to two percent of the population – their coloration is accounted for by a mutation in MC1R. A team of researchers led by Beth Israel Deaconess Medical Center (BIDMC) and Boston University School of Medicine (BUSM) has revealed that the same MC1R mutation...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'